CXCL8 and neoplasm: Additionally, TA-MSCs enhance immunosuppression by altering tumor cell immunogenicity through the downregulation of HLA-I [95, 215], upregulation of PD-L1 via IL-8 secretion [96, 216], and increased expression of CD73 [91].